Skip to main content
Premium Trial:

Request an Annual Quote

VLST, AnaptsyBio Developing Antibody Therapeutics for Autoimmune, Inflammatory Disorders

Premium

This story originally ran on April 7.

Seattle-based biotech firm VLST this week announced a collaboration with AnaptysBio for the generation of novel multi-antigen antibody therapeutics for autoimmune and inflammatory disorders.

VLST discovers and develops novel biologic therapeutics using an approach combining proteomics and bioinformatics.

Under the terms of the agreement, AnaptysBio will generate novel antibodies using its proprietary somatic hypermutation technology platform. VLST will develop and commercialize antibodies developed by AnaptysBio.

AnaptysBio has received an upfront payment and is eligible for certain milestone payments and royalties associated with the development and sale of products stemming from the collaboration, according to a joint statement from the two firms.

No further financial terms were disclosed.

According to VLST's website, the company has used its proteomics platform to identify multiple novel and "potentially druggable targets" for treating hepatitis C.

VLST also is developing a dimeric protein, VLST-007, comprised of human CD47 extracellular domain fused to the fragment crystallizable portion of a human IgG1 molecule. It has completed preclinical development of VLST-007 and is looking for a partner to further develop the product, it added.

Also in development is multikine antibody VLST-002 for autoimmune disorders and inflammatory diseases.

AnaptysBio, based in San Diego, develops therapeutic antibodies.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.